Turnitin
降AI改写
早检测系统
早降重系统
Turnitin-UK版
万方检测-期刊版
维普编辑部版
Grammarly检测
Paperpass检测
checkpass检测
PaperYY检测
Gastric cancer: epidemiology, prevention, classification, and treatment
R Sitarz, M Skierucha, J Mielko… - Cancer management …, 2018 - Taylor & Francis
Gastric cancer is the second most common cause of cancer-related deaths in the world, the
epidemiology of which has changed within last decades. A trend of steady decline in gastric …
epidemiology of which has changed within last decades. A trend of steady decline in gastric …
Anti-angiogenesis for cancer revisited: Is there a role for combinations with immunotherapy?
Angiogenesis is defined as the formation of new blood vessels from preexisting vessels and
has been characterized as an essential process for tumor cell proliferation and viability. This …
has been characterized as an essential process for tumor cell proliferation and viability. This …
Randomized, double-blind, placebo-controlled phase III trial of apatinib in patients with chemotherapy-refractory advanced or metastatic adenocarcinoma of the …
J Li, S Qin, J Xu, J **ong, C Wu, Y Bai, W Liu… - Journal of Clinical …, 2016 - ascopubs.org
Purpose There is currently no standard treatment strategy for patients with advanced
metastatic gastric cancer experiencing progression after two or more lines of chemotherapy …
metastatic gastric cancer experiencing progression after two or more lines of chemotherapy …
The impact of hypoxia on immune state in cancer
K Mortezaee, J Majidpoor - Life sciences, 2021 - Elsevier
Hypoxia is a known feature of solid tumors and a critical promoter of tumor hallmarks.
Hypoxia influences tumor immunity in a way favoring immune evasion and resistance …
Hypoxia influences tumor immunity in a way favoring immune evasion and resistance …
The Italian Research Group for Gastric Cancer (GIRCG) guidelines for gastric cancer staging and treatment: 2015
G De Manzoni, D Marrelli, GL Baiocchi, P Morgagni… - Gastric Cancer, 2017 - Springer
The Italian Research Group for Gastric Cancer (GIRCG) guidelines for gastric cancer staging
and treatment: 2015 | Gastric Cancer Skip to main content Advertisement SpringerLink Account …
and treatment: 2015 | Gastric Cancer Skip to main content Advertisement SpringerLink Account …
Distinct molecular subtypes of gastric cancer: from Laurén to molecular pathology
M Cisło, AA Filip, GJA Offerhaus, B Ciseł… - …, 2018 - pmc.ncbi.nlm.nih.gov
In Western countries the majority of gastric cancers (GC) are usually diagnosed in advanced
stages reporting a 5-year survival rate of only 26%. The Laurén classification of GC was …
stages reporting a 5-year survival rate of only 26%. The Laurén classification of GC was …
Mechanisms of resistance to chemotherapy in gastric cancer
Although surgical resection is the standard curative therapy for gastric cancer, these tumors
are often diagnosed at an advanced stage, when surgery is not recommended. Alternative …
are often diagnosed at an advanced stage, when surgery is not recommended. Alternative …
Targeted therapies for gastric cancer: failures and hopes from clinical trials
Gastric cancer is the third leading cause of cancer mortality worldwide. As surgery is the only
curative treatment strategy and conventional chemotherapy has shown limited efficacy-with …
curative treatment strategy and conventional chemotherapy has shown limited efficacy-with …
Molecular targeted drugs and treatment of colorectal cancer: recent progress and future perspectives
F Geng, Z Wang, H Yin, J Yu, B Cao - Cancer biotherapy & …, 2017 - liebertpub.com
Nowadays, colorectal cancer is the fourth most common type of tumor all over the world.
When diagnosed,∼ 50%–60% of tumors have metastasized, thus resulting in a grim …
When diagnosed,∼ 50%–60% of tumors have metastasized, thus resulting in a grim …
[HTML][HTML] A randomized, double-blind, phase II study of ramucirumab plus docetaxel vs placebo plus docetaxel in Japanese patients with stage IV non-small cell lung …
K Yoh, Y Hosomi, K Kasahara, K Yamada, T Takahashi… - Lung cancer, 2016 - Elsevier
Objectives Ramucirumab plus docetaxel prolongs survival in patients with non-small cell
lung cancer (NSCLC) with disease progression after platinum-based therapy. This phase II …
lung cancer (NSCLC) with disease progression after platinum-based therapy. This phase II …